Fabino Enter

Why is Fabino Enterprises Ltd falling/rising?

As of 18-Jul, the stock price of Fabino Enterprises Ltd is stable at 20.31, with a year-to-date increase of 29.36% despite a 22.21% decline over the past year. Increased investor participation and sector outperformance indicate potential for future growth, despite recent volatility.

As of 18-Jul, the stock price of Fabino Enterprises Ltd is currently stable at 20.31, showing no change (0.00%). Despite this stability, the stock has exhibited a significant year-to-date increase of 29.36%, contrasting with a decline of 8.30% in the benchmark Sensex. However, over the past year, the stock has fallen by 22.21%, while the Sensex has decreased by only 4.99%. <BR><BR>Today's performance indicates that the stock has outperformed its sector by 2.47%, which suggests some positive momentum. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 3122.22% compared to the 5-day average, indicating heightened interest in the stock. <BR><BR>However, the stock has shown erratic trading patterns, having not traded on 5 out of the last 20 days, which may contribute to its volatility. The moving averages indicate that while the stock is performing better than its 5-day and 20-day moving averages, it remains below the longer-term averages (50-day, 100-day, and 200-day). <BR><BR>Overall, while the stock price is currently stable, the combination of strong year-to-date performance, increased investor participation, and sector outperformance suggests potential for future growth, despite the recent historical declines.

Which are the latest news on Fabino Enter?

What does Fabino Enter do?

Fabino Enterprises Ltd is a micro-cap pharmaceutical company, incorporated in 2011, with recent net sales of 1 Cr and a market cap of 4 Cr. It has a P/E ratio of 33.00 and a return on equity of 3.22%.

Overview:<BR>Fabino Enterprises Ltd is a growing pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History:<BR>Fabino Enterprises Ltd was incorporated as "Fabino Life Sciences Private Limited" in 2011 and later converted to a Public Limited Company, changing its name to "Fabino Life Sciences Limited" in 2015. The latest quarterly results reported net sales and profit for June 2021.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2021) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2021) <BR>Market-cap value: INR 4 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 33.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.36 <BR>Return on Equity: 3.22% <BR>Price to Book: 1.01 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Fabino Enter?

As of 10th June, Fabino Enterprises Ltd has a market capitalization of 4.00 Cr, with recent net sales of 1.13 Cr and a net profit of 0.01 Cr. Shareholder's funds are valued at 4.20 Cr, and total assets amount to 17.65 Cr as of March 2025.

As of 10th June, Fabino Enterprises Ltd has a market capitalization of 4.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarter ending June 2021, Fabino Enterprises reported Net Sales of 1.13 Cr and a Net Profit of 0.01 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds are valued at 4.20 Cr and Total Assets amount to 17.65 Cr.

Who are in the management team of Fabino Enter?

The management team of Fabino Enter includes Atul Jain (CMD & Executive Director), Aditya Mahavir Jain (Executive Director & Wholetime Director), Arihant Jain (Non-Executive Director), Tesu Alakh (Independent Non-Executive Director), Gagan Gupta (Independent Non-Executive Director), and Sumit Malik (Non-Executive & Non-Independent Director).

The management team of Fabino Enter includes the following individuals:<BR><BR>1. **Atul Jain** - CMD & Executive Director<BR>2. **Aditya Mahavir Jain** - Executive Director & Wholetime Director<BR>3. **Arihant Jain** - Non-Executive Director<BR>4. **Tesu Alakh** - Independent Non-Executive Director<BR>5. **Gagan Gupta** - Independent Non-Executive Director<BR>6. **Sumit Malik** - Non-Executive & Non-Independent Director<BR><BR>If you have any more questions about the company or its management, feel free to ask!

Who are the peers of the Fabino Enter?

Fabino Enter's peers include Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., and Saroja Pharma In. Most peers exhibit below-average management risk and growth ratings, with Beryl Drugs showing the highest 1-year return at 31.73% and Decipher Labs the lowest at -38.05%.

Peers: The peers of Fabino Enter are Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Growth ratings are Below Average for Beryl Drugs, Decipher Labs, Ganga Pharma., Brawn Biotech, Fabino Enter, and Vivanza Biosci., while Average growth is noted at Unjha Formul. and the rest. Capital Structure is rated Good at Unjha Formul., Average at Ganga Pharma., and Below Average at Beryl Drugs, Decipher Labs, Vivanza Biosci., Brawn Biotech, Fabino Enter, and the rest.<BR><BR>Return Snapshot: Beryl Drugs has the highest 1-year return at 31.73%, while Decipher Labs has the lowest at -38.05%, with Fabino Enter's own 1-year return at -17.94% being higher than Decipher Labs but lower than Beryl Drugs. Additionally, peers with negative six-month returns include Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter.

When is the next results date for Fabino Enterprises Ltd?

The next results date for Fabino Enterprises Ltd is 23 May 2026.

The next results date for Fabino Enterprises Ltd is scheduled for 23 May 2026.

How has been the historical performance of Fabino Enter?

Fabino Enter's historical performance shows stable share capital and gradual increases in total reserves and shareholder's funds, but significant growth in long-term borrowings and total liabilities, with no reported profit or cash flows, indicating a lack of operational profitability. The book value per share slightly increased from Rs 19.59 to Rs 20.02 over the period.

Answer:<BR>The historical performance of Fabino Enter shows a consistent trend in its financial metrics over the past three years.<BR><BR>Breakdown:<BR>Fabino Enter's share capital has remained stable at Rs 2.10 crore from March 2023 to March 2025. Total reserves have shown a gradual increase, rising from Rs 2.01 crore in March 2023 to Rs 2.10 crore in March 2025. Shareholder's funds also increased slightly, from Rs 4.11 crore in March 2023 to Rs 4.20 crore in March 2025. Long-term borrowings have significantly increased, moving from Rs 0.41 crore in March 2023 to Rs 1.79 crore in March 2025, primarily due to an increase in unsecured loans. Total liabilities have risen sharply from Rs 5.00 crore in March 2023 to Rs 17.65 crore in March 2025, reflecting higher trade payables, which increased from Rs 0.37 crore to Rs 11.42 crore over the same period. Total assets have also grown, from Rs 5.00 crore in March 2023 to Rs 17.65 crore in March 2025, with total current assets increasing from Rs 4.78 crore to Rs 17.03 crore. However, the company has reported no profit before tax or cash flows from operating, investing, or financing activities during these years, indicating a lack of operational profitability. The book value per share has seen a slight increase from Rs 19.59 in March 2023 to Rs 20.02 in March 2025.

Is Fabino Enter overvalued or undervalued?

As of October 8, 2025, Fabino Enter is considered very expensive and overvalued, with a PE ratio of 4.83 and disappointing financial performance, including a year-to-date stock return of -30.09%, compared to the Sensex's 4.65% return.

As of 8 October 2025, the valuation grade for Fabino Enter has moved from risky to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 4.83, an EV to EBIT of 6.22, and a ROE of 3.03%. In comparison to its peers, Fabino Enter's PE ratio is significantly lower than Sun Pharma's 34.13 and Divi's Lab's 70.37, indicating that it is trading at a discount relative to these competitors despite its high valuation grade.<BR><BR>Fabino Enter's financial performance has been disappointing, as evidenced by a year-to-date stock return of -30.09%, contrasting sharply with the Sensex's positive return of 4.65% over the same period. This underperformance, combined with its very expensive valuation grade and low profitability ratios, further supports the conclusion that the company is overvalued in the current market environment.

Who are the top shareholders of the Fabino Enter?

The top shareholder of Fabino Enter is promoter Aditya Mahavir Jain, holding 52.38%. The highest public shareholder is Nopea Capital Services Private Limited at 4.71%, while individual investors collectively own 29.18% of the shares.

The top shareholders of Fabino Enter include Aditya Mahavir Jain, who is the promoter with the highest holding at 52.38%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors currently do not hold any shares in the company. The highest public shareholder is Nopea Capital Services Private Limited, holding 4.71%. Additionally, individual investors collectively hold 29.18% of the shares.

Has Fabino Enter declared dividend?

No Dividend History Available